THP-1 CDX Model

The THP-1 cell line is derived from human acute monocytic leukemia, a subtype of acute myeloid leukemia (AML). AML is a heterogeneous hematological malignancy characterized by the rapid proliferation of immature myeloid cells, leading to impaired hematopoiesis and bone marrow failure. THP-1 serves as an indispensable tool for understanding the complex biology, progression, and therapeutic challenges associated with AML, particularly the monocytic subtype. Reflecting key molecular features and genetic mutations often seen in AML patients, THP-1 plays a vital role in preclinical research. Its in vitro and in vivo behavior provides deep insights into leukemic cell growth dynamics, interaction with the bone marrow microenvironment, and sensitivity to therapeutic agents. Researchers widely utilize the THP-1 model to study the molecular drivers of AML, assess the efficacy of potential therapeutic agents, and investigate resistance mechanisms to current treatments.

Model Details

Cancer Location: Intravenous
Cancer Type: Acute Myeloid Leukemia
Model Name: THP-1
Mouse Strain: NOG, NSG

THP-1 Growth Curves

THP-1 CDX Model

Growth of subcutaneous THP-1 in mice (n=5 mice)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.